Acasti Pharma achieves 50% enrollment in STRIVE-ON safety trial

Acasti Pharma announced that the company’s pivotal Phase 3 STRIVE-ON safety trial has exceeded the 50% enrollment milestone. The STRIVE-ON trial, a prospective, open-label, randomized, parallel group trial of GTX-104 compared with oral nimodipine in 100 patients hospitalized for aSAH, initiated patient enrollment in October of 2023. The primary endpoint is safety and will be measured as comparative adverse events, including hypotension, between the two groups.